Home>Topics>Companies>Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

  1. All
  2. Commentary
  3. Stock Reports
  4. Fund Reports
  5. Headlines
  1. EC approves Eylea label expansion

    Headlines

    Mon, 11 Aug 2014

    The European Commission approves Regeneron Pharmaceuticals ' (NASDAQ: REGN ) Eylea (aflibercept) for the treatment of visual impairment caused by diabetic macular edema (DME). The new indication complements

  2. The Case That Regeneron May Be Significantly Undervalued

    Headlines

    Fri, 8 Aug 2014

    appearances may be deceiving. Regeneron Pharmaceuticals , Inc . (NASDAQ: REGN ) is in my view that sort ..... hence. This article evaluates REGN using a sum-of-the-parts ..... pinpoint yet. Introduction : Regeneron is a world-class developer

  3. Regeneron Pharmaceuticals' ( REGN ) CEO Leonard Schleifer on Q2 2014 Results - Earnings Call Transcript

    Headlines

    Tue, 5 Aug 2014

    Regeneron Pharmaceuticals (NASDAQ: REGN ) Q2 2014 Earnings Call August 05, 2014 8:30 am ET Executives ..... Ex Officio Member of Technology Committee and President of Regeneron Research Laboratories Robert J. Terifay - Senior Vice President

  4. UPDATE 3- Regeneron sales top forecast as Eylea picks up steam

    Headlines

    Tue, 5 Aug 2014

    (Adds details on experimental cholesterol drug, updates shares)

  5. New Morningstar Analyst Report for Regeneron Pharmaceuticals Inc

    Stock Reports

    Tue, 5 Aug 2014

    colorectal cancer trials, Regeneron 's oncology drug Zaltrap ..... of its high cost. Eylea is on track to capture ..... acquisition down the road. Regeneron 's prolific monoclonal ..... 6 million in 2012. Regeneron Pharmaceuticals discovers, develops ..... marketed products: Eylea , approved for wet

  6. Regeneron Pharmaceuticals ( REGN ) Q2 2014 Results - Earnings Call Webcast

    Headlines

    Tue, 5 Aug 2014

    The following audio is from a conference call that will begin on August 05, 2014 at 08:30 AM ET. The audio will stream live while the call is active, and can be replayed upon its completion. Listen now Complete Story »

  7. Regeneron sales top forecast as Eylea delivers

    Headlines

    Tue, 5 Aug 2014

    Aug 5 (Reuters) - Regeneron Pharmaceuticals Inc on Tuesday reported quarterly sales above expectations on surging demand for its Eylea treatment for macular degeneration, the leading cause of blindness in the elderly.

  8. Regeneron Pharmaceuticals beats by $0.18, beats on revenue

    Headlines

    Tue, 5 Aug 2014

    Regeneron Pharmaceuticals (NASDAQ: REGN ): Q2 EPS of $2.47 beats by $0.18 . Revenue of $666M (+45.5% Y/Y) beats by $18.01M . Press Release Post your comment!

  9. Regeneron Reports Solid 2Q Eylea Sales, Continued Pipeline Progress; Maintaining Fair Value

    Commentary

    Tue, 5 Aug 2014

    Regeneron reported second-quarter results that ..... better than anticipated, with U.S. Eylea sales rebounding strongly after a sluggish ..... first-quarter results. Rest of world Eylea sales, as reported by partner Bayer ..... Despite higher SG&A costs related to Eylea 's commercialization and increased ..... hypercholesterolemia patients. Importantly, Regeneron also disclosed that in a prespecified

  10. Alirocumab successful in nine Phase 3 trials

    Headlines

    Wed, 30 Jul 2014

    Regeneron Pharmaceuticals (NASDAQ: REGN ) and partner Sanofi (NYSE: SNY ) ( OTCQB:SNYNF ) report that their PCSK9 inhibitor alirocumab met its primary endpoint of

« Prev12345Next »
Content Partners